Stay updated on CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies Clinical Trial
Sign up to get notified when there's something new on the CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies Clinical Trial page.

Latest updates to the CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedNew update timestamps were added (2026-07-06, 2026-07-02, 2026-06-29) and older timestamps removed (2026-07-01, 2026-06-30, 2026-05-26). These entries reflect administrative updates to the study record rather than substantive changes.SummaryDifference0.2%

- Check16 days agoChange DetectedUpdated the study contact information by replacing Nirali N Shah, M.D. with Sara K Silbert, M.D., including new phone and email details. The page's revision tag was updated from v3.6.2 to v3.6.3.SummaryDifference0.3%

- Check23 days agoChange DetectedThe page now shows a new revision number, v3.6.2, replacing the previous v3.6.0. This indicates an internal update to the page rendering without changing the study information displayed.SummaryDifference0.0%

- Check37 days agoChange DetectedThe page now includes new user-focused sections and links such as Check who can join, Find Contact Information, How to Read a Study Record, Common Questions, and How to Join a Study, with recent revision markers (2026-06-10 and 2026-06-09) and a v3.6.0 update. Older sections like Intervention / Treatment and NCI Pediatric Leukemia, Lymphoma Transpl were removed, indicating a reorganization of participation and treatment details.SummaryDifference0.5%

- Check44 days agoChange DetectedA new revision label v3.5.5 was added to the page, indicating a minor platform update rather than substantive changes to the study details.SummaryDifference0.0%

- Check51 days agoChange DetectedThe study title and description were updated to reflect a new, more detailed Phase I/II CD19/CD22-CAR T cell trial in children and young adults with B cell malignancies. The update adds phase-specific design elements, dosing cohorts, and eligibility details, while older wording was removed or superseded to align with the new structure.SummaryDifference3%

Stay in the know with updates to CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies Clinical Trial page.